Sequencing Therapies in CLL

News
Video

The panel shares their thoughts on sequencing the available therapies in patients with CLL.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
The medical characteristics of a patient may heavily factor into the selection of tyrosine kinase inhibition for the treatment of chronic myeloid leukemia.
The toxicity profile of interferon and the limited availability of transplantation established a need for TKI development for chronic myeloid leukemia.
We have the current CAR [T-cell therapies], which target CD19; however, we need others.
Related Content
The overall safety profile of pirtobrutinib was consistent with previously reported trials across various CLL and SLL settings.

Pirtobrutinib Improves PFS in Treatment-Naïve CLL/SLL Without 17p Deletions

Tim Cortese
September 10th 2025
Article
Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Elizabeth Shpall, MD
September 10th 2025
Podcast
The AML Epigenomic Risk model used 946 AML-only peripheral blood or bone marrow samples at diagnosis.

AI Prognostic Tool Confirms Concordance Through Epigenomic Signatures in AML

Tim Cortese
September 10th 2025
Article
Immunotherapy Approaches in AML

Immunotherapy Approaches in AML

Naval Daver, MD
September 10th 2025
Podcast
Leading experts gathered in Orlando, FL, to discuss the current and future state of cellular therapy in oncology at the 2025 ICE-T Symposium.

National ICE-T Conference Aims to Make CAR T Safer and More Available

Tim Cortese
September 10th 2025
Article
Durable Response to CAR T is Associated With Elevated Activation and Clonotypic Expansion of the Cytotoxic Native T Cell Repertoire

Durable Response to CAR T is Associated With Elevated Activation and Clonotypic Expansion of the Cytotoxic Native T Cell Repertoire

American Society for Transplantation and Cellular Therapy
September 10th 2025
Article